Jiksak Bioengineering, Inc.
PrivateLast Round
Series B
Aug 29, 2022
Total Funding Raised
$7.39M
Company Overview
Jiksak Bioengineering, Inc. operates in Healthcare & Life Sciences and is based in Kawasaki. Its latest recorded funding round was a Series B round in August 2022.
Jiksak Bioengineering, Inc. is a biotechnology company that develops therapies for intractable neurodegenerative and neurological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Jiksak Bioengineering, Inc. Comparables
Compare Jiksak Bioengineering, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuCyte | 81% | |
| 28bio | 81% | |
| MicroBrain Biotech | 81% |
For institutional investors. Book with your work email.
Jiksak Bioengineering, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 29, 2022 | ||||
| Series B | Mar 23, 2021 | ||||
| Early Funding | Feb 21, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Jiksak Bioengineering, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CEJ Capital | Series B |
| ANRI株式会社 | Series B, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 7, 2026
Monthly visitors increased 162% MoM to 3.1K.
- Nov 28, 2025
Co-CEO to present Neuron DDS technology at ALS/MND Symposium.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 19, 2026
Jiksak Bioengineering, Inc. aims to establish a versatile drug delivery platform by expanding Neuron DDS to mRNA and other nucleic acid therapeutics for neurological diseases through an AMED-funded collaborative research project in Japan on Oct 19th '26.
For institutional investors. Book with your work email.
Jiksak Bioengineering, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Jiksak Bioengineering, Inc.'s valuation, stock price, and market status.
Is Jiksak Bioengineering, Inc. a public or private company?
Jiksak Bioengineering, Inc. is a private company.
What is the current stock price of Jiksak Bioengineering, Inc.?
Jiksak Bioengineering, Inc. is a private company, so its shares have no public market price. Caplight tracks Jiksak Bioengineering, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Jiksak Bioengineering, Inc. worth (valuation)?
Valuation information for Jiksak Bioengineering, Inc. is not publicly available.
Can I buy Jiksak Bioengineering, Inc. stock?
Jiksak Bioengineering, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Jiksak Bioengineering, Inc.'s last funding round?
Jiksak Bioengineering, Inc.'s most recent funding round was Series B on August 29, 2022.
Who are the main investors in Jiksak Bioengineering, Inc.?
Key investors in Jiksak Bioengineering, Inc. include CEJ Capital, ANRI株式会社.
Will Jiksak Bioengineering, Inc. IPO soon?
No public IPO plans have been announced for Jiksak Bioengineering, Inc..
How can I track Jiksak Bioengineering, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Jiksak Bioengineering, Inc.'s shares on secondary markets.